$1,000,000 – Awarded December 2020
$200,000 – Awarded December 2018
Contraline
Charlottesville, VA
About
Contraline is a medical device company developing a long-lasting, non-hormonal, and reversible male contraceptive using advancements in hydrogel technology. The company was founded in 2015 by Kevin Eisenfrats and Dr. John Herr, and is headquartered in Charlottesville, Virginia.
Our Grant
Contraline has invented a proprietary hydrogel called ADAM™ that is implanted into the vas deferens through a minimally invasive, outpatient procedure. The hydrogel works by blocking sperm from traveling through the vas deferens. Similar to intrauterine devices (IUDs) for women, Contraline’s contraceptive is designed to last for years and be reversible.
MCI’s funding has been used by Contraline to initiate a clinical trial in Australia, where the product will be evaluated in men. Additional funds have been used by Contraline to refine the implantation procedure in preparation for filing with the FDA and initiating further clinical trials.
“Vas-occlusion is a promising non-hormonal male contraceptive approach that has been attempted for decades, yet no product has been realized. Our team has developed a vas-occlusive hydrogel that is easily injectable, safe, and long-lasting. We are constantly improving the product and procedure with a focus on clinical translation and patient satisfaction,” said Kevin Eisenfrats, Co-Founder and CEO of Contraline. “We are honored that MCI has chosen to partner with Contraline to bring the first long-lasting, non-hormonal, and reversible male contraceptive to market.”
Press Releases
Male Contraceptive Initiative Invests $1 Million in Contraline to Conduct Clinical Trial for Long-Lasting, Non-Hormonal Male Contraceptive
November 18, 2020
Announcing A $200K Grant To Contraline
January 24, 2019
More Information
Those interested in receiving updates about Contraline’s progress can sign up at https://www.contraline.com/participate/